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Between 1978 and 1990, 122 men underwent semen analysis before starting sterilising chemotherapy for Hodgkin’s disease.
Eighty-one (66%) had semen quality within the normal range, 25 were oligospermic (520610
6 sperm per ml) and ﬁve were
azoospermic (no sperm in the ejaculate). Semen from 115 men was cryopreserved and after a median follow-up time of 10.1
years, 33 men have utilised stored semen (actuarial rate 27%) and nine partners have become pregnant resulting in 11 live
births and one termination for foetal malformation. Actuarial 10 year rates of destruction of semen before death or utilisation
and death before utilisation are 19% and 13% respectively. This retrospective cohort study demonstrates that approximately
one-quarter of men utilising cryopreserved semen after treatment for Hodgkin’s disease obtain a live birth. The high non-
utilisation rate is intriguing and warrants further investigation.
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Most patients with Hodgkin’s disease can expect prolonged survival
due to the success of chemotherapy regimens which have evolved
since the ﬁrst introduction of MOPP (mustine, vincristine, procar-
bazine and prednisolone) in 1964 (De Vita et al, 1972).
Unfortunately, infertility is a common late effect of treatment
and particularly important since most patients are young adults
at diagnosis (Whitehead et al, 1982). Semen cryopreservation is
currently the only available technique to preserve reproductive
potential in men undergoing potentially sterilising treatments and
in the UK is offered routinely to patients who are under 55 years
of age. However, little information exists as to the beneﬁts of this
policy. In this study, semen quality before and after chemotherapy,
rates of utilisation of cryopreserved semen and reproductive
outcome have been analysed in a cohort of 122 men who presented
to a regional cancer centre with newly diagnosed Hodgkin’s disease
between 1978 and 1990.
PATIENTS AND METHODS
Names of all male patients with newly diagnosed Hodgkin’s disease
registered at the Christie Hospital were cross-matched with the
names of patients referred for semen cryopreservation at St Mary’s
Hospital, Manchester between January 1978 and December 1990.
Permission to gather information from the ﬁles at St Mary’s
Hospital, Manchester was obtained from the Human Fertility and
Embryology Authority. Details of patient age and stage of disease
at diagnosis, treatment given, current disease status, dates and
treatment of relapse, semen analysis before and after treatment,
marital status and number of children fathered prior to diagnosis
of Hodgkin’s disease, use of cryopreserved semen, outcome of
assisted reproduction and natural conceptions following treatment
were obtained from case notes and the reproductive medicine data
base. To compare semen quality between patients with multiple
semen analyses a ‘best’ sample was selected by using a rank-sum
procedure. Brieﬂy, sperm concentration and motility were ranked
independently and in ascending order, then the ranks of concentra-
tion and motility were summed for each sample. The highest rank-
sum was used to select the ‘best’ semen specimen. The Kaplan–
Meier method was used to estimate actuarial rates of semen utilisa-
tion, death without utilisation and destruction of semen without
utilisation from the time of cryopreservation. The log-rank test
was used to compare semen utilisation in men stratiﬁed according
to marital status, number of children and age at diagnosis.
RESULTS
During the 12 year period 1978 to 1990, 122 men with a median
age of 24 years (range 16–44 ) were eligible for inclusion in the
study. As shown in Figure 1, the annual rate of referrals made
for semen cryopreservation increased over this time. All patients
received MVPP (mustine, vinblastine, prednisolone, procarbazine)
or ChlVPP/EVA hybrid (chlorambucil, vinblastine, prednisolone,
procarbazine, etoposide, vincristine, doxorubicin) chemotherapy
either as adjuvant treatment following radiotherapy in early stage
disease (MVPP) or for advanced stage disease (MVPP or
ChlVPP/EVA hybrid) followed by radiotherapy to sites of intial
bulk or residual masses. These regimens have equivalent gonadal
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to the pelvis following chemotherapy in three patients and to sites
distant from the abdomen or pelvis in 82 patients.
Semen analysis before treatment
A median of four semen samples was analysed for each patient
(range 1–7). For 121 out of 122 patients with complete data,
the median sperm concentration was 50610
6 per ml (range 0–
306) and median sperm motility was 60 (range 0–90). Azoosper-
mia (no sperm present in the ejaculate) and oligospermia
(520610
6 per ml) were present in ﬁve and 25 patients respec-
tively and severe oligospermia (410610
6 per ml) was present in
13 out of 25 patients.
According to WHO criteria (WHO Laboratory Manual, 1992)
66% of patients in this series had a semen quality within the
normal range (sperm concentration 420610
6 per ml and
450% motile sperm) (Figure 2). Semen was cryopreserved for
115 out of 122 patients (Figure 1). Reasons for not cryopreserving
semen were azoospermia (n=5) and immotile sperm (n=2).
Semen analysis after treatment
Of 115 patients who cryopreserved semen, 97 patients were alive
and disease free, one patient was alive with disease, 16 patients
had died and there was incomplete data for one patient when this
analysis was performed. After treatment, 74 patients requested
semen analysis at least once (median=2, range 1–7) and at varying
times following treatment depending on personal circumstances. At
the ﬁrst analysis, a median interval of 2.9 years (range 0.1–12.3)
after completion of chemotherapy, the majority were azoospermic
(68 out of 74) and four patients were oligospermic (1610
6 per
ml). Normal spermatogenesis was present in two patients (sperm
concentrations of 25 million per ml and 50 million per ml), 79
and 54 months after treatment. Both patients had received only
three of a planned eight cycles of MVPP. At subsequent analyses,
recovery of spermatogenesis was detected in seven previously
azoospermic patients although all remained severely oligospermic
(sperm concentration 510610
6 per ml). Overall, a degree of
recovery of spermatogenesis occurred in 13 out of 74 patients at
a median interval of 5.1 years (range 3.3–13.1) after treatment.
To our knowledge, four patients in whom spermatogenesis recov-
ered have fathered children naturally.
Assisted reproduction using cryopreserved semen
Data regarding utilisation was complete for 113 out of 115 patients
who stored semen. The actuarial rate of utilisation 10 years from
storage is 27%, the rate of destruction of semen without utilisation
and before death of the patient is 19% and the rate of death with-
out utilisation is 13% (Figure 3). Cryopreserved samples from 29
patients have been destroyed due to death (n=15), recovery of
spermatogenesis (n=4) or at patient request with no reason speci-
ﬁed (n=10). Patients who remain alive who have neither used nor
destroyed cryopreserved semen have been followed for a median of
10.1 years. At the time of analysis, cryopreserved semen had been
utilised for assisted reproduction by 33 couples. Grouping of
patients according to whether or not they already had children
or marital status at diagnosis revealed no group of patients who
were signiﬁcantly more or less likely to attempt assisted reproduc-
tion using cryopreserved semen (data not shown). Similarly,
analysis by age at diagnosis also showed no signiﬁcant difference
in utilisation after 10 years (Figure 4) although numbers in each
group were small.
During the course of this study a number of methods of assisted
reproduction were used as treatments evolved and new techniques
were introduced. At the start of the study in 1978, the only option
was simple vaginal insemination or artiﬁcial insemination with
husband’s sperm (AIH). In vitro fertilisation (IVF) was offered
from 1984 onwards, and intracytoplasmic sperm injection (ICSI)
from 1995 (Van Steirteghem et al, 1993). AIH was superceded by
direct insemination into the uterine cavity (IUI) in 1995 (Horne
et al, 1998). Of 33 couples receiving assisted reproduction, AIH
was used by 28, IUI by two, and IVF or ICSI by three. Seven
couples who originally received AIH went on to have IVF or ICSI
as these techniques became available. In nine out of 33 couples, 10
pregnancies occurred of which eight resulted from AIH and two
from IVF. One pregnancy (AIH) was terminated due to foetal
malformation (hydrocephalus and cervical hygroma; normal female
karyotype) but the remaining nine pregnancies resulted in the birth
of 8 healthy singletons and one triplet of males to give a live birth
rate of 27%. The triplet of males was the result of implantation of
frozen thawed embryos from a second attempt at IVF using cryo-
preserved semen and ICSI, a particularly unusual case that has
already been reported elsewhere (Horne et al, 2001). In 23 couples
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Figure 1 Men referred to Regional Fertility Centre between 1978 and
1990 for semen analysis and cryopreservation before treatment of Hodg-
kin’s disease.
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Figure 2 Sperm motility vs concentration in 121 men with Hodgkin’s dis-
ease before start of treatment. Results for the ‘best’ samples analysed are
shown (see Materials and Methods). Samples lying in the right upper quad-
rant, as deﬁned by the horizontal line drawn at 50% motility and the vertical
line drawn at 20 million per ml, are within the normal range for semen qual-
ity according to WHO criteria.
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of reproductive outcomes).
DISCUSSION
The use of combination chemotherapy regimens has dramatically
improved the prognosis for patients with Hodgkin’s disease.
However, gonadal toxicity is common and for a number of years
patients have been routinely counselled regarding this important
late effect of treatment and offered semen cryopreservation. This
policy initially met with the concern that sperm quality was
adversely affected by Hodgkin’s disease itself and semen was there-
fore unlikely to be of use for cryopreservation and subsequent
assisted reproduction (Whitehead et al, 1982). Several investigators
have demonstrated relatively poor semen quality in patients with
Hodgkin’s disease compared to healthy controls (Redman et al,
1987; Shekarriz et al, 1995), and patients with non-Hodgkin’s
lymphomas (Botchan et al, 1997; Lass et al, 1998) although, consis-
tent with the current study, a signiﬁcant proportion of men with
Hodgkin’s disease are found to have semen quality within the
normal range at diagnosis.
There have been dramatic advances in reproductive medicine
since the ﬁrst reports of successful artiﬁcial insemination using
cryopreserved semen from patients with Hodgkin’s disease (Scam-
mell et al, 1985). The increasing availability of techniques such as
ICSI means that semen containing even very low numbers of
sperm should, nevertheless be cryopreserved (Lass et al, 1999).
Furthermore, although in this series one pregnancy was terminated
for foetal malformation there is no known increased risk of this
complication in pregnancies resulting from the use of cryopre-
served semen stored by patients with Hodgkin’s disease or other
malignancies (Lansac et al, 1997).
This study conﬁrms the high rates of sterility previously
reported for MVPP and ChlVPP/EVA hybrid chemotherapy
(Whitehead et al, 1982; Clark et al, 1995) and highlights the
increasing use of semen cryopreservation over time which probably
reﬂects both a greater awareness of the importance of fertility
issues for patients with a good prognosis and the availability of
appropriate facilities. Although there are anecdotal reports of
successful pregnancies following the use of cryopreserved semen
in men with Hodgkin’s disease (Scammell et al, 1985; Redman et
al, 1987; Milligan et al, 1989), to our knowledge, there are no
published data describing the proportion of long term survivors
of Hodgkin’s disease in the UK who attempt assisted reproduction
and achieve success. Our retrospective data show that most patients
have not used their cryopreserved semen (27% utilisation 10 years
from storage, Figure 3) the reasons for which are unclear. Although
factors such as disease status following treatment, age, marital
status or number of children at diagnosis might be expected to
have a bearing on reproductive decision making, our results impli-
cate other, as yet unidentiﬁed factors. In the UK these may include
lack of immediate access to assisted reproduction treatment as
many health authorities do not currently provide NHS funding.
The Regional IVF and Donor Insemination treatment centre at
St Mary’s Hospital in Manchester, for example, does provide
NHS treatment but has a 3–4 year waiting list, does not treat
couples who already have children living with them and has treated
male factor infertility since only 1994. Workers from Australia
(Audrins et al, 1999) have reported an even lower utilisation rate
(7%) but in this study the mean follow-up time was only 3 years,
a factor that may be important in evaluating this end point.
In the retrospective cohort reported here, approximately one-
quarter have utilised cryopreserved semen following treatment for
Hodgkin’s disease and of these, approximately one-quarter have
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Figure 4 Cumulative rates of semen utilisation according to age at diag-
nosis of Hodgkin’s disease (Kaplan–Meier method).
Table 1 Reproductive outcome of 33 couples who have utilised cyropreserved semen
Method of assisted reproduction Number of patients Number of pregnancies Number of live births
Artiﬁcial insemination (AIH) or intrauterine insemination (IUI) 30 8 (in 7 women)
a 7
In vitro fertilisation (IVF) or intracytoplasmic 10 2 4 (1 set of triplets from frozen embryos
sperm injection (ICSI) (7 had failed previous AIH) obtained by IVF using ICSI)
aOne woman had a termination of pregnancy for foetal abnormality followed by a healthy livebirth.
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Figure 3 Cumulative rates of semen utilisation, death before utilisation
and sample destruction without utilisation or death in patients with Hodg-
kin’s disease (Kaplan–Meier method).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 381–384had a live birth. Vaginal insemination was the most commonly
used method of assisted reproduction and the live birth rate of
27% for all methods used is consistent with, if not better than,
expected outcomes for infertile couples (Human Fertilisation and
Embryology Authority, 1999, annual report). However, pregnancy
was not achieved in the majority of couples who wished to have
a child and ways to improve reproductive potential in this group
of patients including earlier and more frequent use of advanced
reproductive techniques such as IVF and ICSI need to be consid-
ered. It should be remembered, however, that procedures more
complex than artiﬁcial insemination are signiﬁcantly invasive and
women with normal fertility may ﬁnd the demands made too
stressful and/or time consuming. In addition, these techniques
usually involve either a long waiting list or considerable expense
if undertaken privately. Our ﬁnding that most patients have not
yet used cryopreserved semen is intriguing and warrants further
investigation. Do these men and their partners consider themselves
still too young to start a family or have they opted never to have
children? Is assisted reproduction acceptable to patients? Do they
have access to all the reproductive technology currently available?
And ﬁnally, are there fears regarding safety such as risk of disease
transmission?
In addition to employing less toxic chemotherapy regimens wher-
ever possible (Kulkarni et al, 1997) other strategies to overcome the
impact of chemotherapy on reproductive function include the use of
donor sperm for artiﬁcial insemination or IVF of the partner’s eggs,
hormonal manipulations to enhance recovery of spermatogenesis
(Meistrich, 1998) and cryopreservation with subsequent autotrans-
plantation of testicular germ cells (Brook et al, 2001). There is no
doubt, however, that men about to embark on a programme of ster-
ilising chemotherapy should be offered semen cryopreservation as
routine in the knowledge that the live birth rate following utilisation
is at least 25%, a ﬁgure that is set to rise as a consequence of steady
advances in reproductive medicine.
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